کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2975374 | 1179355 | 2011 | 9 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Mise au point sur les bêtabloquants pour les médecins vasculaires en 2012
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
arteriopathy - آرتروپاتیRisk - خطرRisque - خطرArtériopathie - سرخرگیPression artérielle - فشار خونHypertension - فشار خون بالاCentral pressure - فشار مرکزیcardiovascular - قلبی عروقیCardiovasculaire - قلبی و عروقیBêtabloquants - مسدود کننده های بتاBeta blockers - مسدودکننده گیرنده آدرنرژیک بتا، بلوک کننده بتا
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
کاردیولوژی و پزشکی قلب و عروق
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Since they were launched on the market in 1964, cardiovascular indications for beta-blockers have been validated and accepted worldwide. Numerous studies and meta-analysis have confirmed their benefits. They reduce mortality in post infarction and acute coronary syndrome populations and also in people with stable coronary heart disease. Moreover, heart failure with systolic left ventricular dysfunction is a major indication for this therapeutic class, providing a 30% decrease in mortality. In patients with permanent atrial fibrillation, beta-blockers are recommended for rate control. In hypertension patients, first-line drug treatment with beta-blockers is currently discussed. Indeed, several studies have shown that patients randomized in the beta-blocker arms experienced more coronary heart and cerebrovascular diseases than comparators. Their lesser effect on central blood pressure decrease could partially explain those results. Nevertheless, beta-blockers are still considered as first-line drugs for hypertension in the French and European guidelines. Long-term comparative studies focusing on central blood pressure are needed. Concerning the other indications for beta-blockers in vascular diseases, their use perioperatively to reduce surgical cardiovascular risk raised much hope, but the most recent results are disappointed and even suggest possible higher mortality. Finally, except for patients with critical ischemia of the lower limbs, presence of peripheral artery disease should probably be considered as a condition favoring their prescription.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal des Maladies Vasculaires - Volume 36, Issue 6, December 2011, Pages 339-347
Journal: Journal des Maladies Vasculaires - Volume 36, Issue 6, December 2011, Pages 339-347
نویسندگان
S. Mairesse, J. Blacher, M.-E. Safar,